Physician profile
Peri Gunay
NPI 1154376010
$1,108.17
in general payments reported to CMS, 2019-2025
19 companies · $494 in 2025
The $494 reported for 2025 was more than what 92% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $64.14 · 2021: $18.69 · 2022: $70.85 · 2023: $65.62 · 2024: $83.53 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $169.42 | 2019 | |
| Supernus Pharmaceuticals, INC. | $167.92 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $146.50 | 2022-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Tris Pharma INC | $123.51 | 2019 | |
| Sanofi Pasteur INC. | $88.15 | 2020-2025 | |
| Neos Therapeutics, LP | $51.86 | 2025 | Cotempla Xr-Odt |
| Cranial Technologies, INC | $50.11 | 2023-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $46.93 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $44.36 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $29.02 | 2025 | Pediarix, Bexsero, Penmenvy |
| Pfizer INC. | $24.84 | 2020 | |
| Alk-Abello, INC | $24.77 | 2025 | Neffy |
| Abbott Laboratories | $23.39 | 2025 | Id Now Instrument |
| Collegium Pharmaceutical, INC. | $21.71 | 2025 | Jornay Pm |
| Krystal Biotech INC | $21.63 | 2025 | Vyjuvek |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.02 | 2022 | |
| Mylan Pharmaceuticals INC. | $18.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.48 | 2020 | |
| Verrica Pharmaceuticals INC. | $18.03 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peri Gunay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.